Movatterモバイル変換


[0]ホーム

URL:


AR029538A1 - PHARMACEUTICAL COMPOSITIONS OF ESTROGEN AGENTS - Google Patents

PHARMACEUTICAL COMPOSITIONS OF ESTROGEN AGENTS

Info

Publication number
AR029538A1
AR029538A1ARP010103094AARP010103094AAR029538A1AR 029538 A1AR029538 A1AR 029538A1AR P010103094 AARP010103094 AAR P010103094AAR P010103094 AARP010103094 AAR P010103094AAR 029538 A1AR029538 A1AR 029538A1
Authority
AR
Argentina
Prior art keywords
ethers
alkyl
halogenated
esters
pharmaceutical compositions
Prior art date
Application number
ARP010103094A
Other languages
Spanish (es)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth CorpfiledCriticalWyeth Corp
Publication of AR029538A1publicationCriticalpatent/AR029538A1/en

Links

Classifications

Landscapes

Abstract

Translated fromSpanish

Comprende nuevos sistemas portadores o excipientes farmacéuticos y formulaciones farmacéuticas orales que comprenden como ingrediente activo raloxifeno, amoxifeno, droloxifeno, arzoxifeno, o CP 336156, o análogos de los mismos, o un compuesto de las formulas 1 o 2 donde Z es una porcion seleccionada del grupo 3, 4 o 5 donde R1 está seleccionado de H, OH o ésteres C1-12 de éteres de alquilo de los mismos, benciloxi, o halogeno; o éteres C1-4 halogenados; R2, R3, R4, R5 y R6 son H, OH o ésteres C1-12 o éteres de alquilo de los mismos, halogenos, o éteres C1-4 halogenados, ciano alquilo C1-6 o CF3 con la condicion de que cuando R1 es H R2 no sea OH; Y es la porcion de formula 6; R7 y R8 son alquilo o concatenados conjuntamente forman un anillo que contiene nitrogeno, opcionalmente sustituido o una sal farmacéuticamente aceptable de los mismos; y excipientes elegidos entre rellenadores farmacéuticos, deslizantes, lubricantes, agentes lubricantes y antioxidantes.It comprises new pharmaceutical carrier or excipient systems and oral pharmaceutical formulations comprising as active ingredient raloxifene, amoxifene, droloxifene, arzoxyphene, or CP 336156, or analogs thereof, or a compound of formulas 1 or 2 where Z is a portion selected from the group 3, 4 or 5 where R1 is selected from H, OH or C1-12 esters of alkyl ethers thereof, benzyloxy, or halogen; or halogenated C1-4 ethers; R2, R3, R4, R5 and R6 are H, OH or C1-12 esters or alkyl ethers thereof, halogens, or halogenated C1-4 ethers, cyano C1-6 alkyl or CF3 with the proviso that when R1 is H R2 is not OH; And it is the portion of formula 6; R7 and R8 are alkyl or concatenated together form an optionally substituted nitrogen-containing ring or a pharmaceutically acceptable salt thereof; and excipients chosen from pharmaceutical fillers, glidants, lubricants, lubricating agents and antioxidants.

ARP010103094A2000-07-062001-06-28 PHARMACEUTICAL COMPOSITIONS OF ESTROGEN AGENTSAR029538A1 (en)

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
US21619200P2000-07-062000-07-06

Publications (1)

Publication NumberPublication Date
AR029538A1true AR029538A1 (en)2003-07-02

Family

ID=22806095

Family Applications (1)

Application NumberTitlePriority DateFiling Date
ARP010103094AAR029538A1 (en)2000-07-062001-06-28 PHARMACEUTICAL COMPOSITIONS OF ESTROGEN AGENTS

Country Status (26)

CountryLink
US (2)US20020031548A1 (en)
EP (1)EP1309327B1 (en)
JP (1)JP2004502733A (en)
KR (2)KR100862174B1 (en)
CN (2)CN1450895A (en)
AR (1)AR029538A1 (en)
AT (1)ATE453391T1 (en)
AU (2)AU2001271741B2 (en)
BR (1)BR0112242A (en)
CA (1)CA2415058A1 (en)
CY (1)CY1109915T1 (en)
DE (1)DE60140945D1 (en)
DK (1)DK1309327T3 (en)
EA (1)EA006386B1 (en)
ES (1)ES2336304T3 (en)
HU (1)HUP0301422A3 (en)
IL (2)IL153647A0 (en)
MX (1)MXPA02012891A (en)
NO (1)NO20030030L (en)
NZ (1)NZ523330A (en)
PL (1)PL204866B1 (en)
PT (1)PT1309327E (en)
SI (1)SI1309327T1 (en)
TW (1)TWI294777B (en)
WO (1)WO2002003987A2 (en)
ZA (1)ZA200301004B (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
CN1240375C (en)*2001-05-012006-02-08辉瑞产品公司 Process for the preparation of low dose pharmaceutical compositions with uniform drug distribution and potency
EP1531807A4 (en)*2002-06-132007-10-31Wyeth CorpBazedoxifene treatment regimens
PA8576201A1 (en)2002-07-102004-05-26Pfizer Prod Inc PHARMACEUTICAL COMPOSITION THAT HAS A DISTRIBUTION AND UNIFORM POWER OF FARMACO
RU2006123939A (en)*2004-01-132008-02-20Вайет (Us) TREATMENT OF OSTEOPOROSIS RELATED TO AROMATASE INHIBITORS
AU2005233133A1 (en)2004-04-072005-10-27WyethCrystalline polymorph of a bazedoxifene acetate
US7683052B2 (en)2004-04-072010-03-23WyethCrystalline polymorph of bazedoxifene acetate
WO2005099677A1 (en)*2004-04-082005-10-27WyethBazedoxifene acetate solid dispersion formulations
WO2005100315A1 (en)*2004-04-082005-10-27WyethBazedoxifene ascorbate as selective estrogen receptor modulator
US7781478B2 (en)2004-07-142010-08-24Ptc Therapeutics, Inc.Methods for treating hepatitis C
CN100358517C (en)*2004-09-282008-01-02马晶Tamoxifen citrate oral disintegrating tablet and its preparation method
WO2006052254A2 (en)*2004-11-102006-05-18Teva Pharmaceutical Industries Ltd.Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
EP1787642A1 (en)*2004-11-102007-05-23Teva Pharmaceutical Industries Ltd.Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
US8367105B2 (en)2004-11-102013-02-05Teva Pharmaceutical Industries, Ltd.Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
EP1863464B1 (en)*2005-03-312009-11-11WyethO-desmethylvenlafaxine and bazedoxifene combination product and uses thereof
EP1898888A2 (en)*2005-06-292008-03-19Wyeth a Corporation of the State of DelawareFormulations of conjugated estrogens and bazedoxifene
WO2007024961A2 (en)*2005-08-242007-03-01WyethBazedoxifene acetate formulations and manufacturing process thereof
AU2012275036B2 (en)*2005-08-242016-05-19Wyeth LlcBazedoxifene acetate formulations and manufacturing process thereof
WO2008093878A1 (en)*2007-02-012008-08-07Takeda Pharmaceutical Company LimitedTablet preparation without causing a tableting trouble
CA2696984C (en)*2007-10-162013-04-23Pharmathen S.A.Improved pharmaceutical composition containing a selective estrogen receptor modulator and method for the preparation thereof
EP2271320A4 (en)*2008-04-022011-05-18Reddys Lab Ltd DrRaloxifene pharmaceutical formulations
ITMI20091109A1 (en)2009-06-232010-12-24Wyeth Corp POLYMORPHO D FORM OF BAZEDOXIFENE ACETATE AND METHODS FOR ITS PREPARATION
EP2448562B1 (en)2009-07-022013-11-06Synthon B.V.Raloxifene composition
ES2436841T3 (en)2009-10-272014-01-07Wyeth Llc Bazedoxifene formulations with antioxidants
ITBO20110461A1 (en)2011-07-292013-01-30Alfa Wassermann Spa PHARMACEUTICAL COMPOSITIONS INCLUDING RIFAXIMINA, PROCESSES FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF VAGINAL INFECTIONS.
KR102145641B1 (en)2012-06-052020-08-18다케다 야쿠힌 고교 가부시키가이샤Solid preparation
WO2013182169A1 (en)2012-06-072013-12-12Zentiva, K. S.Process of preparation of an antioxidant-free polymorphically and chemically stable formulation of bazedoxifene acetate
WO2013182170A1 (en)2012-06-072013-12-12Zentiva, K. S.Enhancement of dissolution rate from pharmaceutical composition comprising bazedoxifene acetate
CN103006570B (en)*2012-10-082013-12-25孙维会Arzoxifene immediate-release pellets and preparation method thereof
JP6602779B2 (en)2014-02-132019-11-06インサイト・コーポレイション Cyclopropylamines as LSD1 inhibitors
EP3626713B1 (en)2014-02-132021-09-29Incyte CorporationCyclopropylamines for use as lsd1 inhibitors
CN103830197A (en)*2014-03-142014-06-04崔书豪Hydrochloric acid raloxifene dispersible tablet and preparation method thereof
WO2016007722A1 (en)2014-07-102016-01-14Incyte CorporationTriazolopyridines and triazolopyrazines as lsd1 inhibitors
DK3277278T3 (en)2015-04-022020-04-06Theravance Biopharma R&D Ip Llc Combination dosage form of a myopioid receptor antagonist and an opioid
MA51438A (en)2015-04-032021-04-14Incyte Corp HETEROCYCLIC COMPOUNDS USED AS LSD1 INHIBITORS
SI3334709T1 (en)2015-08-122025-03-31Incyte Holdings Corporation LSD1 INHIBITOR SALTS
US11786471B2 (en)*2016-07-112023-10-17Wuhan Ll Science And Technology Development Co. Ltd.Complex disintegrant system for oral solid preparation and oral solid preparation comprising said complex disintegrant system
KR101683193B1 (en)*2016-10-202016-12-08전남대학교산학협력단Composition for Improving, Preventing or Treating Menopausal Syndrome Comprising Non-reducing end of Unsaturated Mannuronic Acid Oligosaccharides as Active Ingredient
KR101683192B1 (en)*2016-10-202016-12-08전남대학교산학협력단Composition for Improving, Preventing or Treating Menopausal Syndrome Comprising Non-reducing end of Unsaturated Mannuronic Acid Oligosaccharides as Active Ingredient
CN107951034B (en)*2017-12-012021-03-23郑州拓洋生物工程有限公司Effervescent vitamin preparation and its preparing process
WO2020047198A1 (en)2018-08-312020-03-05Incyte CorporationSalts of an lsd1 inhibitor and processes for preparing the same
RU2732291C1 (en)*2020-02-132020-09-15Открытое акционерное общество "Фармстандарт-Лексредства" (ОАО "Фармстандарт-Лексредства")Medicinal agent based on althaea officinalis herb for treating colds and acute respiratory diseases
CN115526105A (en)*2022-10-092022-12-27北部湾大学Cutter wear prediction method based on multivariate fast iterative filter decomposition method

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3552727A (en)*1968-09-181971-01-05American Air Filter CoGas scrubbing apparatus
US4133814A (en)1975-10-281979-01-09Eli Lilly And Company2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en)1981-04-031983-11-29Eli Lilly And CompanyAntiestrogenic and antiandrugenic benzothiophenes
JP3029742B2 (en)*1992-08-202000-04-04株式会社東芝 Image correction device
JPH0674903A (en)*1992-08-261994-03-18Sumitomo Metal Ind Ltd Method and apparatus for detecting microdefects in flat material to be detected
FR2698788B1 (en)1992-12-091995-03-03Union Pharma Scient Appl Effervescent pharmaceutical composition containing ibuprofen and process for its preparation.
US5342133A (en)*1992-12-231994-08-30Hewlett-Packard CompanyPaper moving system for a printer/plotter
US5332727A (en)1993-04-291994-07-26Birkmayer U.S.A.Stable, ingestable and absorbable NADH and NADPH therapeutic compositions
US5811120A (en)*1994-03-021998-09-22Eli Lilly And CompanySolid orally administerable raloxifene hydrochloride pharmaceutical formulation
US5478847A (en)1994-03-021995-12-26Eli Lilly And CompanyMethods of use for inhibiting bone loss and lowering serum cholesterol
IL112746A (en)*1994-03-021999-12-31Lilly Co EliOrally administrable pharmaceutical formulation comprising raloxifene hydrochoride
US5552412A (en)1995-01-091996-09-03Pfizer Inc5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US5919800A (en)1995-02-281999-07-06Eli Lilly And CompanyBenzothiophene compounds, intermediates, compositions, and methods
SG64896A1 (en)*1995-02-281999-05-25Lilly Co EliBenzothiophene compounds intermediates compositions and methods
US5510357A (en)1995-02-281996-04-23Eli Lilly And CompanyBenzothiophene compounds as anti-estrogenic agents
ATE206701T1 (en)*1996-04-192001-10-15American Home Prod ESTROGENIC COMPOUNDS
TW397821B (en)1996-04-192000-07-11American Home Produits Corp3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US5780497A (en)1996-04-191998-07-14American Home Products Corporation2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5880137A (en)*1996-04-191999-03-09American Home Products Corporation2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
CA2306343C (en)1997-10-152010-08-03American Home Products CorporationNovel aryloxy-alkyl-dialkylamines
EP1098636A1 (en)*1998-07-232001-05-16Novo Nordisk A/SA wet granulation method for preparing a stable pharmaceutical formulation

Also Published As

Publication numberPublication date
EA006386B1 (en)2005-12-29
TWI294777B (en)2008-03-21
IL153647A0 (en)2003-07-06
US20080269198A1 (en)2008-10-30
DK1309327T3 (en)2010-04-26
EP1309327B1 (en)2009-12-30
NZ523330A (en)2005-07-29
MXPA02012891A (en)2003-10-24
AU2001271741B2 (en)2006-10-19
EP1309327A2 (en)2003-05-14
WO2002003987A3 (en)2002-07-11
BR0112242A (en)2003-06-24
US7759386B2 (en)2010-07-20
KR100862174B1 (en)2008-10-09
ES2336304T3 (en)2010-04-12
CN101416949A (en)2009-04-29
PT1309327E (en)2010-02-23
US20020031548A1 (en)2002-03-14
HUP0301422A3 (en)2006-07-28
KR20070110454A (en)2007-11-16
CN1450895A (en)2003-10-22
PL365875A1 (en)2005-01-10
KR20030023689A (en)2003-03-19
ZA200301004B (en)2004-05-05
NO20030030D0 (en)2003-01-03
CA2415058A1 (en)2002-01-17
PL204866B1 (en)2010-02-26
CY1109915T1 (en)2014-09-10
EA200300122A1 (en)2003-06-26
IL153647A (en)2011-03-31
HUP0301422A2 (en)2003-09-29
NO20030030L (en)2003-03-03
ATE453391T1 (en)2010-01-15
KR100894027B1 (en)2009-04-22
JP2004502733A (en)2004-01-29
SI1309327T1 (en)2010-03-31
WO2002003987A2 (en)2002-01-17
DE60140945D1 (en)2010-02-11
AU7174101A (en)2002-01-21

Similar Documents

PublicationPublication DateTitle
AR029538A1 (en) PHARMACEUTICAL COMPOSITIONS OF ESTROGEN AGENTS
AR030064A1 (en) METHODS TO INHIBIT THE UTEROTROPHIC EFFECTS OF ESTROGEN AGENTS
AR046297A1 (en) DPP INHIBITORS - IV METHODS TO PREPARE THEM AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AS ACTIVE AGENTS
AR029216A1 (en) NON-PEPTIDIC INHIBITING COMPOUNDS OF THE VLA-4 DEPENDENT CELL UNION IN THE TREATMENT OF INFLAMMATORY, AUTOIMMUNE AND RESPIRATORY DISEASES; PHARMACEUTICAL COMPOSITION AND TREATMENT PROCEDURE
ES2081187T3 (en) NEW NAFTIL-ALQUIL-AMINAS, ITS PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
KR20050085991A (en)Compounds exhibiting thrombopoietin receptor agonism
ZA919181B (en)Oxazolopyridine derivatives,processes for preparing these and pharmaceutical compositions containing them
PT1447399E (en) 2-OXO-1-PYRROLIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USES
PE20020721A1 (en) QUINUCLIDINE DERIVATIVES AS ANTIMUSCARINAL AGENTS M3
AR031930A1 (en) MCH ANTAGONISTS AND ITS USE IN THE TREATMENT OF OBESITY
SE0201659D0 (en) Modified release pharmaceutical formulation
UY27384A1 (en) PROSTAGLANDINA ANALOGS
EE05103B1 (en) Pharmaceutical formulations containing azetidine derivatives, azetidine derivatives and methods for their preparation
SE8106642L (en) PIPERAZINYLBENOHETHEROCYCLIC COMPOUNDS AND PROCEDURES FOR PREPARING THEREOF
WO2002003976A3 (en)Combinations of bisphosphonates, estrogenic agents and optionally estrogens
WO2002003988A3 (en)Use of substituted indole compounds for treating neuropeptide y-related conditions
MXPA05007341A (en)2-piperidone derivatives as prostaglandin agonists.
ES2118203T3 (en) NEW BENZOPYRANIC DERIVATIVES, THEIR PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
WO2002003986A3 (en)Use of substituted indole compounds for treating breast disorders
ES2159922T3 (en) NEW DERIVATIVES OF BENCIMIDAZOL, BENZOXAZOL AND BENZOTIAZOL, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
NO20014119L (en) Medication containing a sulfopyranosylacylglycerol derivative
HUT59124A (en)Process for producing 2-(aminoalkyl)-5-(arylalkyl)-1,3-dioxane derivatives and pharmaceutical compositions comprising such derivatives as active ingredient
MX9207427A (en) NEW ESTILE COMPOUNDS OF BUTYL HYDROXYTOLUENE-OMEGA-PIRIDILO AND PHARMACEUTICAL COMPOSITION CONTAINING THEM.
MX2024012470A (en)Cdk9 inhibitors
ATE371644T1 (en) NEW ALKALOID DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

Legal Events

DateCodeTitleDescription
FCRefusal

[8]ページ先頭

©2009-2025 Movatter.jp